Pipeline overview

Forward Pharma has established a pipeline of immunomodulatory compounds with the potential to mature into a family of development programs in multiple indications with several different chemical entities.

Forward Pharma's lead drug candidate is FP 187, a new generation of a clinically validated approach in psoriasis and other inflammatory diseases. FP 187 is an oral small molecule that demonstrated promising pharmacokinetics and tolerability in Phase I testing in healthy volunteers.

FP 187 is currently undergoing Phase II testing in 18 centers in Germany and is foreseen to include at least 180 patients with moderate to severe plaque psoriasis. This Phase II study, A randomised, double blind, placebo controlled efficacy and safety trial of different doses/dose regimens of FP187 compared to placebo in moderate to severe plaque psoriasis, will assess the proportion of patients achieving PASI 75 (reduction in the PASI score of 75% from baseline), and several other secondary endpoints including Quality of Life. The Company expects data to be available Q3, 2011.